Document Detail

Licensee over-reliance on conservatisms in NRC guidance regarding the release of patients treated with 131I.
MedLine Citation:
PMID:  17993847     Owner:  NLM     Status:  MEDLINE    
Medical licensees are required to comply with U.S. Nuclear Regulatory Commission (NRC) regulations pertaining to the release of patients administered radioactive material. However, use of the associated NRC guidance expressed in NUREG-1556, Volume 9, is completely optional and has been shown to be overly conservative. Rigid adherence to the guidance recommendations has placed an undue burden on nuclear medicine therapy patients and their families, as well as licensees responsible for ensuring compliance with NRC requirements. More realistic guidance has been published by other responsible professional societies and will be presented in this work. These more realistic calculations allow for higher releasable activity levels than the widely adopted NUREG levels, particularly for thyroid cancer patients. The guidance-suggested releasable activity limit is similar to our calculational result for hyperthyroid patients, 2.1 GBq (57 mCi) compared to 2.3 GBq (62 mCi), but is significantly lower for thyroid cancer patients, 6.6 GBq (179 mCi) vs. 16.9 GBq (457 mCi) using the regulatory definition of the total effective dose equivalent (TEDE). Higher limits are both possible and reasonable, if the permissible extra-regulatory definition of the TEDE is used in which the effective dose equivalent (EDE), rather than the deep-dose equivalent (DDE), is determined. We maintain that professionals evaluating compliance with the NRC requirements for patient release, pursuant to 10 CFR 35.75, should use the procedures presented here and not rely automatically on the NUREG.
Jeffry A Siegel; Carol S Marcus; Michael G Stabin
Related Documents :
8837327 - Endogenously labeled thyroid hormones (131i-t3/t4) in sera of patients with differentia...
20305407 - Tc-99m sestamibi thyroid imaging in patients on chronic amiodarone treatment: a compari...
9177377 - Increased serum concentration of soluble cd30 in patients with graves' disease and hash...
3917657 - Thyroid hormones in conditions of chronic malnutrition. a study with special reference ...
21253827 - Growth, final height and endocrine sequelae in a uk population of patients with hurler ...
9331147 - Increased esophageal chemoreceptor sensitivity to acid in patients after successful rev...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Health physics     Volume:  93     ISSN:  0017-9078     ISO Abbreviation:  Health Phys     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-11-12     Completed Date:  2008-01-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985093R     Medline TA:  Health Phys     Country:  United States    
Other Details:
Languages:  eng     Pagination:  667-77     Citation Subset:  IM    
Nuclear Physics Enterprises, Marlton, NJ, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Hypothyroidism / radiotherapy
Iodine Radioisotopes / therapeutic use*
Patient Discharge / legislation & jurisprudence*
Radiation Monitoring / legislation & jurisprudence,  methods*
Radiation Protection / legislation & jurisprudence,  methods*
Radiopharmaceuticals / therapeutic use*
Radiotherapy Dosage
Thyroid Neoplasms / radiotherapy
Reg. No./Substance:
0/Iodine Radioisotopes; 0/Radiopharmaceuticals

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
Next Document:  Correction factors for more accurate estimates of exposure rates near radioactive patients: experime...